Nevro Corp (1N7N)

58.0000
-3.5000(-5.69%)
  • Volume:
    0
  • Bid/Ask:
    0.0000/0.0000
  • Day's Range:
    58.0000 - 58.0000
  • Type:Equity
  • Market:Germany
  • ISIN:US64157F1030
  • WKN:A12EPL

1N7N Overview

Prev. Close
61.5
Day's Range
58-58
Revenue
-
Open
58
52 wk Range
58-151
EPS
-
Volume
0
Market Cap
2.08B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
5
P/E Ratio
-
Beta
-
1-Year Change
-57.29%
Shares Outstanding
34,904,128
Next Earnings Date
-
What is your sentiment on Nevro Corp?
or
Vote to see community's results!

Nevro Corp Company Profile

Nevro Corp. is a global medical device company that provides solutions for the treatment of chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain, with the Senza Omnia platform. Its Senza System, Senza II System, and the Senza Omnia System are the SCS systems that delivers Nevro's 10 kilohertz (kHz) therapy. The Senza system is focused on creating traditional low frequency electrical impulses and its HF10 therapy, which allows for pain relief without paresthesia. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. The HF10 therapy delivers waveforms at 10,000 Hertz (Hz) pulse rate with a statistically driven and clinically verified programming algorithm.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsSellSellSellSellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • whoo
    0
    • Focus: Industrials spike to major resistance, Retail sector clears key trendline, Boeing takes flight, Apple extends triangle breakout, XLI, XRT, BA, AAPL, NVRO https://www.marketwatch.com/story/charting-a-bull-flag-breakout-sp-500-knifes-within-view-of-record-high-3028-2019-09-12?mod=mw_quote_news
      0
      • Nevro price target raised to $205 from $175 at Truist Securities, stock rated buy
        0
        • Nevro to Highlight New Clinical Evidence at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting
          0
          • DUMP!! No earnings! not a "value" company!!
            1
            • going down
              1
              Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
              Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.